Latest News & Features
Big Pharma
The Court of Justice of the European Union has clarified when pharmaceutical patent owners may rely on the Specific Mechanism to prevent parallel imports of their products. 19 February 2015
Big Pharma
The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports. 19 February 2015
article
Two years after its launch, the LSIPR monthly is having a re-brand. This issue will be the final one published in a PDF format, as in March we are switching to a ‘digital first’ strategy. 19 February 2015
Americas
As Myriad seems to have thrown in the towel in its fight to protect patents covering its BRCA diagnostic tests, LSIPR asks whether the gene patent’s days are numbered in the US, and takes a look at its fortunes in other jurisdictions. 19 February 2015
Big Pharma
The unitary patent and Unified Patent Court will have wide-ranging implications for life sciences companies. In the first of what will be a regular column on the topics by law firm Taylor Wessing, Paul England explores current developments on issues such as costs and judges. 19 February 2015
Big Pharma
A US court has ruled that an AstraZeneca patent covering asthma inhaler Pulmicort Respules is invalid, allowing generic drug makers to enter the market with their own versions. 17 February 2015
Americas
The Canadian government has given a scathing assessment of Eli Lilly’s patenting practices in its formal response to the pharmaceutical company’s CAD $500 million lawsuit against it. 16 February 2015
Genetics
The High Court of Australia is set to consider the Myriad Genetics case concerning whether isolated genetic material is patentable subject matter. 16 February 2015
Americas
Law firm Kaye Scholer has added a team of three life sciences and technology lawyers to its intellectual property group. 13 February 2015
Americas
Novartis has sued drug company BPI Labs for alleged patent infringement after it requested permission to market a generic version of Novartis’s bone cancer drug Zometa. 12 February 2015